Navigation Links
BioMS Medical to present at EQUITIES Conference
Date:4/15/2008

tatements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that MBP8298 will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)...  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ) ... and commercialization of a once-daily, oral therapy for the ... financial results for the period ended June 30, 2014. ... Reported cash and cash equivalents totaling $37.4 million on ... 2013.  , Reported a net loss of $3.9 ...
(Date:7/25/2014)... 25, 2014 Sinovac Biotech Ltd. (Nasdaq: ... China , today announced that it will release ... 30, 2014, after market close on Thursday, August 14, 2014 ... the market opening on Friday, August 15, 2014, at 8:00 ... Standard Time) to review the Company,s financial results and provide ...
(Date:7/24/2014)... July 24, 2014 Gain recognition ... Supply Chain of the biotech industry. Nominations are ... Awards, brought to you by the Bio ... of supply chain management professionals for the past ... stakeholders of the Biotech industry – Manufacturers, Service ...
(Date:7/24/2014)... 2014  ECC West Africa, LLC (ECC) signed a ... University College Hospital (UCH) Ibadan Board of Management for ... design, construct, and operate and maintain a new, state-of-the-art ... Under the first of the 4-phase project, ECC will ... applications. UCH Ibadan intends to finance and develop the ...
Breaking Biology Technology:Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2
...  Amgen (NASDAQ: AMGN ) today announced that it ... results on Thursday, Jan. 26, 2012 after the close of ... conference call with the investment community at 2:00 p.m. Pacific ... Kevin Sharer, chairman and chief executive officer, and other members ...
... SPO Medical Inc. ( SPOM ), a ... in portable monitoring devices, announced today an update to ... strategy for fiscal 2012 primarily based on the completion ... consumer wellness devices. SPO currently has three ...
... team have shown that they can prevent, or even reverse, ... dogs. The disease in humans and dogs is caused ... severe and progressive vision loss. It is one of the ... "Every single abnormal feature that defines the disease in ...
Cached Biology Technology:Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results 2SPO Updates Shareholders on 2012 Corporate Strategy 2SPO Updates Shareholders on 2012 Corporate Strategy 3Gene therapy research from Penn Vet & Scheie Eye Inst. cures retinitis pigmentosa in dogs 2Gene therapy research from Penn Vet & Scheie Eye Inst. cures retinitis pigmentosa in dogs 3
(Date:7/27/2014)... -- Microorganisms like bacteria and fungi can evade treatment ... or antifungal drugs. These permanent mutations were once thought ... evolve. Now a new study has shown that microorganisms ... known as epimutations -- to gain the benefits of ... mechanism was discovered in a fungus called Mucor circinelloides, ...
(Date:7/27/2014)... data from over 18,000 patients, scientists have identified ... in Parkinson,s disease, including six that had not ... Nature Genetics , was partially funded by the ... scientists working in NIH laboratories. , "Unraveling the ... the multiple mechanisms involved in this complex disease, ...
(Date:7/25/2014)... and some of the smoke from those fires is drifting ... the Moderate Resolution Imaging Spectroradiometer (MODIS) aboard the Aqua satellite ... over the Great Lakes region of the United States. ... 23, 2014 (first image feature highlighted below) clearly shows the ... In the image, it is over Manitoba and parts ...
Breaking Biology News(10 mins):Scientists discover new, noncommittal mechanism of drug resistance 2Scientists discover new, noncommittal mechanism of drug resistance 3NIH scientists find 6 new genetic risk factors for Parkinson's 2
... relatively new phenomenon in shopping, digital coupons show great ... and usability of a specific type of electronic coupon ... team has found some interesting and important preliminary findings ... used them, why they used them and what problems ...
... of Pennsylvania say that species are still accumulating on ... past. In the study, published in the journal ... computational approach to infer the dynamics of species diversification ... nine patterns of diversification as alternative models, they examined ...
... This release is available in Spanish . ... known as hardening of the arteries, according to results ... with laboratory mice. The research provides the first direct ... lesions, symptomatic of atherosclerosis, from increasing in size in ...
Cached Biology News:Impending death for paper coupons? 2Impending death for paper coupons? 3Penn biologists say species accumulate on Earth at slower rates than in the past 2Blueberries help fight artery hardening, lab animal study indicates 2
... N. Fernandez and G. Butcher (1998). ... subject of much research in the immunology ... structure of MHC proteins and in their ... are now faced with the prospect of ...
DALT GRADIENT MAKER,230V, 1 EA. Category: 2D DALT Systems....
actin from rabbit muscle Cell Biology Cytoskeletal Probes Actin and Actin Probes...
Rat whole blood (Sprague-Dawley, averaging 7-8 weeks of age, either sex) is collected at the time of slaughter and refrigerated within 6 hours, and processed and frozen within 24 hours. The serum is ...
Biology Products: